Provepharm signs license agreement with Daiichi Sankyo to provide methylthioninium chloride Proveblue solution for injection to Japan

Daiichi Sankyo will resolve the unmet need for an approved methylthioninium chloride injectable drug in Japan

01-Dec-2011 - France

Provepharm announced that it has entered into an exclusive licensing agreement with Daiichi Sankyo to make Provepharm’s injectable medicinal product, Methylthioninium chloride Proveblue, available in Japan. The Proveblue medicinal product is used for the treatment of methaemoglobinaemia induced by life-threatening medicinal and chemical products.

Under this agreement Provepharm grants Daiichi Sankyo exclusive rights to methylthioninium chloride Proveblue solution for injection in Japan. Daiichi Sankyo will be responsible for the submission of a marketing authorization application and for all commercial activities relating to the product in this country. Commercial terms of the deal were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances